Pulmatrix (PULM) Change in Accured Expenses (2013 - 2026)
Pulmatrix (PULM) posted Change in Accured Expenses of $147000.0 for Q1 2026, up 219.51% sequentially from -$123000.0 in Q4 2025, and up 16.67% YoY from $126000.0 in Q1 2025.
Pulmatrix (PULM) Change in Accured Expenses (2013 - 2026) Analysis & Trends
Pulmatrix has reported Change in Accured Expenses for 14 years, with the latest figure at $147000.0 in Q1 2026.
- Quarterly Change in Accured Expenses rose 16.67% year-over-year to $147000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$42000.0 (up 96.46% YoY) and the FY2025 annual result came in at -$63000.0, up 85.62% from the prior year.
- Change in Accured Expenses improved to $147000.0 in Q1 2026 per PULM's latest filing, from -$123000.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $1.1 million in Q3 2022 and troughed at -$1.6 million in Q3 2024.
- A 5-year average of -$60529.4 and a median of $16000.0 in 2025 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses tumbled 630.26% in 2022, then surged 3545.83% in 2024.
- Over 5 years, Change in Accured Expenses stood at -$1.1 million in 2022, then dropped by 18.29% to -$1.3 million in 2023, then soared by 92.61% to -$97000.0 in 2024, then fell by 26.8% to -$123000.0 in 2025, then surged by 219.51% to $147000.0 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered $147000.0, -$123000.0, and $16000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Pulmatrix | 5.46 Mn | 5.46 Mn | - | -44,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -44,000.00 |
| Jun 30, 2026 | -44,000.00 |
| Mar 31, 2026 | 147,000.00 |
| Mar 31, 2026 | 147,000.00 |
| Dec 31, 2025 | -123,000.00 |
| Dec 31, 2025 | -123,000.00 |
| Sep 30, 2025 | 16,000.00 |
| Sep 30, 2025 | 16,000.00 |
| Jun 30, 2025 | -82,000.00 |
| Jun 30, 2025 | -82,000.00 |
| Mar 31, 2025 | 126,000.00 |
| Mar 31, 2025 | 126,000.00 |
| Dec 31, 2024 | -97,000.00 |
| Dec 31, 2024 | -97,000.00 |
| Sep 30, 2024 | -1.57 Mn |
| Sep 30, 2024 | -1.57 Mn |
| Jun 30, 2024 | 350,000.00 |
| Jun 30, 2024 | 350,000.00 |
| Mar 31, 2024 | 875,000.00 |
| Mar 31, 2024 | 875,000.00 |